Drug Profile
Eflornithine/sulindac - Panbela Therapeutics
Alternative Names: CPP-1X/sul; CPP-1X/sulindac; CPP1-x/sulindac; Flynpovi; Sulindac/CPP-1X; Sulindac/eflornithine - Panbela Therapeutics; TP 09Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator University of Arizona; University of California at Irvine
- Developer Cancer Prevention Pharmaceuticals; National Cancer Institute (USA); Panbela Therapeutics
- Class Antineoplastics; Basic amino acids; Diamino amino acids; Indenes; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Ornithine decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Familial adenomatous polyposis
- Phase III Colorectal cancer
- No development reported Pancreatic cancer
Most Recent Events
- 05 Sep 2023 Panbela Therapeutics receives patent protection for production process of eflornithine/sulindac in Chile
- 05 Sep 2023 Panbela Therapeutics has patent pending for eflornithine/sulindac in multiple countries
- 04 Sep 2023 Panbela Therapeutics has patent protection for eflornithine/sulindac in USA, Australia, Mexico and Taiwan before September 2023